company background image
UBM logo

Ulisse Biomed BIT:UBM Stock Report

Last Price

€1.45

Market Cap

€31.3m

7D

-0.7%

1Y

-37.2%

Updated

27 Mar, 2024

Data

Company Financials +

UBM Stock Overview

Ulisse Biomed S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy.

UBM fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Ulisse Biomed S.p.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ulisse Biomed
Historical stock prices
Current Share Price€1.45
52 Week High€2.52
52 Week Low€1.36
Beta0.59
1 Month Change-6.75%
3 Month Change-15.20%
1 Year Change-37.23%
3 Year Changen/a
5 Year Changen/a
Change since IPO-54.98%

Recent News & Updates

A Look At The Fair Value Of Ulisse Biomed S.p.A. (BIT:UBM)

Jun 24
A Look At The Fair Value Of Ulisse Biomed S.p.A. (BIT:UBM)

We Think Ulisse Biomed (BIT:UBM) Can Afford To Drive Business Growth

Feb 17
We Think Ulisse Biomed (BIT:UBM) Can Afford To Drive Business Growth

Recent updates

A Look At The Fair Value Of Ulisse Biomed S.p.A. (BIT:UBM)

Jun 24
A Look At The Fair Value Of Ulisse Biomed S.p.A. (BIT:UBM)

We Think Ulisse Biomed (BIT:UBM) Can Afford To Drive Business Growth

Feb 17
We Think Ulisse Biomed (BIT:UBM) Can Afford To Drive Business Growth

Shareholder Returns

UBMIT BiotechsIT Market
7D-0.7%4.3%1.3%
1Y-37.2%-2.7%25.2%

Return vs Industry: UBM underperformed the Italian Biotechs industry which returned -1.1% over the past year.

Return vs Market: UBM underperformed the Italian Market which returned 26.4% over the past year.

Price Volatility

Is UBM's price volatile compared to industry and market?
UBM volatility
UBM Average Weekly Movement5.5%
Biotechs Industry Average Movement7.4%
Market Average Movement4.2%
10% most volatile stocks in IT Market7.8%
10% least volatile stocks in IT Market2.6%

Stable Share Price: UBM's share price has been volatile over the past 3 months.

Volatility Over Time: UBM's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20159Matteo Pettihttps://www.ulissebiomed.com

Ulisse Biomed S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It provides various tests and reagents for sexually transmitted diseases and HPV.

Ulisse Biomed S.p.A. Fundamentals Summary

How do Ulisse Biomed's earnings and revenue compare to its market cap?
UBM fundamental statistics
Market cap€31.28m
Earnings (TTM)-€1.68m
Revenue (TTM)€90.91k

344.0x

P/S Ratio

-18.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UBM income statement (TTM)
Revenue€90.91k
Cost of Revenue€1.06m
Gross Profit-€967.89k
Other Expenses€707.82k
Earnings-€1.68m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.078
Gross Margin-1,064.71%
Net Profit Margin-1,843.32%
Debt/Equity Ratio0.2%

How did UBM perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.